Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV003222568 | SCV003915987 | pathogenic | Glanzmann thrombasthenia | 2023-01-17 | reviewed by expert panel | curation | The NM_000419.5(ITGA2B):c.2415_2416del (p.Asp805GlufsTer11) frameshift variant in exon 24 is predicted to result in a premature stop codon in biologically-relevant-exon 25 of 30 and is predicted to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). At least one patient (Patient 10 in PMID:19172520/GT database record 167) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia (PP4_moderate). Additionally, αIIbβ3 surface expression was reduced to <10%, as measured by flow cytometry. Patient 10 (PMID: 19172520/GT database record 167) is homozygous for this variant (0.5pt; PM3_Supporting). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PVS1, PP4_Moderate, PM2_Supporting, PM3_Supporting (VCEP specifications version 2.1). |